Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish company Laccure has developed a new health product for the treatment and prevention of bacterial vaginosis in women.
Subscribe to our email newsletter
Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age which is caused due to an imbalance of naturally occurring vaginal bacterial flora.
Laccure CEO Dr Jeanette Robertsson said: "We are proud to announce that the final development stage, the up-scaling of the manufacturing process for Laccure Pessary, our new antibiotic-free, non-prescription product for the treatment and prevention of bacterial vaginosis, is now completed."
The new Laccure Pessary is developed based on a proprietary substance that releases lactic acid over several days to decrease the elevated vaginal pH.
This easy to insert and was found to cure BV in 80% of the women after a single dose, during clinical studies.
Laccure Pessary is CE-marked as a Class IIa medical device and is now ready for market introduction in the EU/EES countries.
The company is considering the sale of the company to a potential buyer that will launch Laccure Pessary in the market.